TipRanks
Go Ultimate55% OFF

Rapport Therapeutics, Inc. (RAPP) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Rap-219Epilepsy, Focal Epilepsy, Focal SeizurePhase IIIRecruitingStudy Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal SeizuresMay 11, 2026―
Rap-219Focal Epilepsy, Focal Seizure, EpilepsyPhase IIIRecruitingStudy Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1Apr 16, 2026
Rap-219Epilepsy, Focal Onset Seizure, Focal Seizure, Focal Epilepsy, Seizure, Refractory Focal EpilepsyPhase IIRecruitingA Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresOct 08, 2025
Rap-219Bipolar 1 DisorderPhase IIRecruitingStudy Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderMay 30, 2025
Rap-219Focal Onset SeizuresPhase IICompletedStudy Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal EpilepsyApr 17, 2024

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Rapport Therapeutics, Inc. (RAPP) have in its pipeline
Rapport Therapeutics, Inc. RAPP is currently developing the following drugs: Rap-219. These drug candidates are in various stages of clinical development as the company works toward FDA approval.